Zacks Research Issues Optimistic Estimate for TEVA Earnings

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Investment analysts at Zacks Research lifted their FY2024 earnings per share estimates for shares of Teva Pharmaceutical Industries in a report issued on Monday, November 4th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $2.30 per share for the year, up from their prior estimate of $2.29. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.34 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ Q4 2024 earnings at $0.67 EPS, Q3 2026 earnings at $0.79 EPS and FY2026 earnings at $2.77 EPS.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, November 6th. The company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.63 by $0.04. The company had revenue of $4.33 billion for the quarter, compared to analyst estimates of $4.08 billion. Teva Pharmaceutical Industries had a negative net margin of 5.73% and a positive return on equity of 41.43%.

Several other research analysts have also weighed in on TEVA. UBS Group increased their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Barclays increased their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Finally, JPMorgan Chase & Co. raised their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $19.67.

Teva Pharmaceutical Industries Trading Down 2.3 %

Shares of TEVA stock opened at $17.10 on Thursday. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 2.52. The company has a market capitalization of $19.37 billion, a price-to-earnings ratio of -20.11, a PEG ratio of 1.25 and a beta of 0.87. The firm has a 50-day moving average price of $17.94 and a 200 day moving average price of $17.10. Teva Pharmaceutical Industries has a twelve month low of $8.55 and a twelve month high of $19.31.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Large investors have recently made changes to their positions in the company. Renaissance Technologies LLC boosted its stake in Teva Pharmaceutical Industries by 13.4% during the 2nd quarter. Renaissance Technologies LLC now owns 8,728,563 shares of the company’s stock valued at $141,839,000 after purchasing an additional 1,031,400 shares in the last quarter. Maple Rock Capital Partners Inc. lifted its stake in Teva Pharmaceutical Industries by 68.3% during the first quarter. Maple Rock Capital Partners Inc. now owns 4,363,401 shares of the company’s stock valued at $61,568,000 after purchasing an additional 1,770,000 shares during the last quarter. Truist Financial Corp boosted its stake in shares of Teva Pharmaceutical Industries by 7.0% during the 2nd quarter. Truist Financial Corp now owns 3,885,251 shares of the company’s stock worth $63,135,000 after acquiring an additional 254,483 shares in the last quarter. Swiss National Bank increased its stake in Teva Pharmaceutical Industries by 0.5% in the 3rd quarter. Swiss National Bank now owns 3,342,900 shares of the company’s stock worth $60,239,000 after purchasing an additional 15,300 shares in the last quarter. Finally, National Pension Service raised its holdings in shares of Teva Pharmaceutical Industries by 107.3% during the third quarter. National Pension Service now owns 3,170,640 shares of the company’s stock valued at $57,135,000 after acquiring an additional 1,640,940 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.